Patents by Inventor Henryk T. Dudek

Henryk T. Dudek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
    Patent number: 11566248
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of PCSK9 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of PCSK9 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hypercholesterolemia, atherosclerosis, and/or one or more symptoms or complications thereof.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: January 31, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Henryk T. Dudek, Jihye Park
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20220396793
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 15, 2022
    Inventors: Bob Dale BROWN, Henryk T. DUDEK
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20220396799
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 15, 2022
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Cheng LAI
  • COMPOSITIONS AND METHODS FOR MODULATING PNPLA3 EXPRESSION
    Publication number: 20220364098
    Abstract: Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with PNPLA3 expression.
    Type: Application
    Filed: April 13, 2022
    Publication date: November 17, 2022
    Inventors: Utsav SAXENA, Henryk T. DUDEK, Marc ABRAMS, Anton TURANOV, Bob Dale BROWN
  • COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
    Publication number: 20220340909
    Abstract: Oligonucleotides are provided herein that inhibit KHK expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with KHK expression.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 27, 2022
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Utsav SAXENA, Jihye PARK, Marc ABRAMS, Martin Lee KOSER
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11459566
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 4, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11408002
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: August 9, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20220228149
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 21, 2022
    Inventors: Bob Dale BROWN, Henryk T. DUDEK
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11359203
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: June 14, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11312960
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: April 26, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11312961
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 26, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11286488
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 29, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11208658
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: December 28, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
    Publication number: 20210238606
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of PCSK9 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of PCSK9 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hypercholesterolemia, atherosclerosis, and/or one or more symptoms or complications thereof.
    Type: Application
    Filed: April 1, 2019
    Publication date: August 5, 2021
    Inventors: Henryk T. DUDEK, Jihye PARK
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA
    Publication number: 20210230604
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 29, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double stranded RNA
    Patent number: 11066672
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 20, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 11060093
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: July 13, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11053502
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20210180061
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: July 1, 2020
    Publication date: June 17, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20210180068
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: July 1, 2020
    Publication date: June 17, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Cheng LAI